• 1
    Morgentaler A. Testosterone and prostate cancer: an historical perspective on a modern myth. Eur Urol. 2006; 50: 935-939.
  • 2
    Salonia A, Gallani A, Briganti A. Preoperative hypogonadism is not an independent predictor of high-risk disease in patients undergoing radical prostatectomy. Cancer 2011; 117: 39533962.
  • 3
    Morgentaler A, Bruning CO 3rd, DeWolf WC. Incidence of occult prostate cancer among men with low total or free serum testosterone. JAMA. 1996; 276: 1904-1906.
  • 4
    Rhoden EL, Morgentaler A. Risks of testosterone-replacement therapy and recommendations for monitoring. N Engl J Med. 2004; 350: 482-492.
  • 5
    Calof OM, Singh AB, Lee ML, et al. Adverse events associated with testosterone replacement in middle-aged and older men: a meta-analysis of randomized, placebo-controlled trials. J Gerontol A Biol Sci Med Sci. 2005; 60: 1451.
  • 6
    Cooper CS, Perry PJ, Sparks AE, MacIndoe JH, Yates WR, Williams RD. Effect of exogenous testosterone on prostate volume, serum and semen prostate specific antigen levels in healthy young men. J Urol. 1998; 159: 441.
  • 7
    Huggins C, Hodges CV. Studies on prostatic cancer. I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res. 1941; 1: 293-297.
  • 8
    Morgentaler A, Traish AM. Shifting the paradigm of testosterone and prostate cancer: the Saturation Model and the limits of androgen-dependent growth. Eur Urol. 2009; 55: 310-321.
  • 9
    Traish AM, Williams DF, Hoffman ND, Wotan HH. Validation of the exchange assay for the measurement of androgen receptors in human and dog prostates. Prog Clin Biol Res. 1988; 262: 145.
  • 10
    Roddam AW, Allen NE, Appleby P, Key TJ; Endogenous Hormones Prostate Cancer Collaborative Group. Endogenous sex hormones and prostate cancer: a collaborative analysis of 18 prospective studies. J Natl Cancer Inst. 2008; 100: 170.
  • 11
    Morgentaler A, Rhoden EL. Prevalence of prostate cancer among hypogonadal men with prostate-specific antigen levels of 4.0ng/mL or less. Urology. 2006; 68: 1263-1267.
  • 12
    Thompson IM, Pauler DK, Goodman PJ, et al. Prevalence of prostate cancer among men with a prostate-specific antigen level <4 ng per milliliter. N Engl J Med. 2004; 350: 2239-2246.
  • 13
    Karamanolakis D, Lambou T, Bogdanos J, et al. Serum testosterone: A potentially adjunct screening test for the assessment of the risk of prostate cancer among men with modestly elevated PSA values (> or =3.0 and <10.0 ng/ml). Anticancer Res. 2006; 26: 3159-3166.
  • 14
    Rhoden EL, Riedner CL, Morgentaler A. The ratio of serum testosterone to prostate specific antigen predicts prostate cancer in hypogonadal men. J Urol. 2008; 179: 1741-1745.
  • 15
    Nishiyama T, Ikarashi T, Hashimoto Y, Suzuki K, Takahashi K. Association between the dihydrotestosterone level in the prostate and prostate cancer aggressiveness using the Gleason score. J Urol. 2006; 176: 1387-1391.
  • 16
    Teloken C, Da Ros CT, Caraver F, Weber FA, Cavalheiro AP, Graziottin TM. Low serum testosterone levels are associated with positive surgical margins in radical retropubic prostatectomy: hypogonadism represents bad prognosis in prostate cancer. J Urol. 2005; 174: 2178-2180.
  • 17
    Massengill JC, Sun L, Moul JW, et al. Pretreatment TT level predicts pathological stage in patients with localized prostate cancer treated with radical prostatectomy. J Urol. 2003; 169: 1670-1675.
  • 18
    Yamamoto S, Yonese J, Kawakami S, et al. Preoperative serum testosterone level as an independent predictor of treatment failure following radical prostatectomy. Eur Urol. 2007; 52: 696.
  • 19
    Chodak GW, Vogelzang NJ, Caplan RJ, et al; for the Zoladex Study Group. Independent prognostic factors in patients with metastatic (stage D2) prostate cancer. JAMA. 1991; 265: 618-621.
  • 20
    Morgentaler A. Two years of testosterone therapy associated with decline in prostate-specific antigen in a man with untreated prostate cancer. J Sex Med. 2009; 6: 574-577.